Led · Equity · Oct 2025

EVerZom is a biotechnology company building a proprietary GMP-compliant bioproduction platform to generate therapeutic exosomes from mesenchymal stem cells. Its approach couples exosomes with biomaterials to improve delivery and efficacy across multiple indications. The lead candidate, EVerGel, targets Crohn’s complex perianal fistulas and is scheduled to enter the clinic in 2026, while Eviv is in pre-clinical development for acute-on-chronic liver failure (ACLF). Additional exploratory programs span ophthalmology, broader regenerative medicine applications, and extra-pharma opportunities such as cosmetics and veterinary health. Proceeds from the latest round will finance the first clinical trial of EVerGel, extend the platform into hepatology and dermatology, and further scale industrial manufacturing capabilities. No revenue or user metrics have been disclosed to date.

Participated · Equity · Sep 2025

Dianosic is a biotechnology company specializing in nasal drug-delivery solutions, notably a biorésorbable nasal implant. The implant is designed to treat chronic allergic rhinitis and rhinosinusitis. The company is also developing nose-to-brain delivery approaches aimed at neurological diseases such as Parkinson's and Alzheimer's. Dianosic announced a €7 million fundraising to accelerate its clinical and industrial development. The round is led by Aptar (Illinois), a global leader in drug-delivery systems, with participation from Noshaq (Liège), Capital Grand Est (Strasbourg) and Finovam Gestion (Lille). Co-founder and president Philippe Bastide said the financing validates the technology and will speed the company’s clinical and industrial progress. Dianosic develops therapeutic solutions for debilitating ENT conditions, including the ARIS family of treatments and the commercial CAVI-T device. The company intends to use new funding to finance a preclinical in vivo study and to launch a phase I clinical trial of its ARIS-R solution for chronic allergic rhinitis. In parallel it will continue developing ARIS-S for chronic sinusitis and explore other ENT applications. Dianosic also plans to use the funds to enhance the technical capability of its team. The company co-founded by Marc Augustin and CEO Philippe Bastide counts Prof. Christian Debry as scientific advisor. Its CAVI-T asymmetrical intranasal balloon is CE-marked, FDA-registered, and has been commercially available in Europe and the Middle East since 2021. Dianosic develops innovative medical devices for the management of ENT conditions. Its core product is CAVI-T, an asymmetrical intranasal balloon for hemostasis that stops spontaneous or postoperative nasal bleeding with low-pressure compression; CAVI-T was CE-marked in February 2020 and is patent-protected in France with planned coverage in Europe, the US, Japan and China. The company is also developing the Active Resorbable Intranasal Scaffold (ARIS) to deliver steroids for long-term (12-month) management of chronic sinusitis without requiring prior surgery. Dianosic intends to use its new funding to support the European launch of CAVI-T and to pursue ARIS development. The company was founded in July 2017 by Marc Augustin, Philippe Bastide and Pr Christian Debry and is incubated by SEMIA with support from the Grand Est regional ecosystem. Financially, Dianosic closed a first funding round of more than €1.5M in a mix of capital and non-dilutive funding.

Participated · Series A · Jan 2025

Keey Aerogel develops silica aerogel produced from construction waste with a patented closed‑loop process that recycles CO₂ and ethanol, which it markets as the only “green” aerogel. The material is ultra‑light (98% air), available as powder, granules, or integrated into thin flexible forms, and offers thermal, acoustic, and fire‑resistant properties. Initial commercial focus includes construction customers and electric‑vehicle battery applications, where its fire‑resistant material can delay thermal runaway spread by 5–10 minutes. Founded in 2015, the company completed seven years of R&D, secured three patents, and opened a pilot plant in Alsace in 2022; it is currently in a pre‑industrial phase supplying major European clients. Keey aims to replicate its pilot site by adding three production lines and to build a network of local factories to enable short supply chains and European manufacturing sovereignty. The company previously raised an initial €1.5M round and has now closed a larger round to fund industrialisation, team expansion, and new production sites.

Participated · Seed · Oct 2023

RDS is a medtech company focused on remote patient monitoring. Its flagship product, MultiSense, is a patented telemonitoring system that the company develops, manufactures and markets. The company collaborates with international research initiatives such as DARE and 5G-OR and has been incubated at SEMIA/Quest for Health while being accelerated by PariSanté Campus. Emphasizing an eco-conscious approach, RDS aims to set new standards for telemonitoring across Europe. With its latest funding, the firm plans to expand commercialization in France, Germany and the broader European market and to conduct additional clinical trials to support reimbursement applications. The team is simultaneously preparing for FDA registration with the goal of entering the U.S. market in 2028. Elie Lobel leads the company as CEO, and no revenue or user metrics have been disclosed.

Participated · Series A · Jul 2023

Founded in 2016, Exeliom Biosciences engineers live-bacterial, NOD2-targeting immunomodulators to boost patients’ innate immune responses. Its lead candidate, EXL01, is a Faecalibacterium prausnitzii-derived therapy that reprograms macrophages and the tumour micro-environment to overcome resistance to existing treatments. EXL01 is currently being tested in three Phase 2 oncology trials alongside immune-checkpoint inhibitors, including what the company calls the largest randomised Phase 2 study worldwide of a bacterial therapy in gastric cancer. The programme also includes a Phase 2 trial in Crohn’s disease and a study aimed at preventing recurrent Clostridioides difficile infection. Fresh capital will fund proof-of-concept Phase 2 work, preparation for a new U.S. cancer indication and broader international expansion. To date, Exeliom has secured nearly €30 million in combined dilutive and non-dilutive financing, underscoring strong investor confidence in its precision immunotherapy platform.